Browse by category

Both metabolic and bariatric surgery (MBS) and glucagon-like peptide-1 receptor agonist (GLP-1RA) medications improve cardiovascular health in people with obesity, but surgery was associated with significantly greater reductions in long-term cardiovascular risk, according to a study by researchers from the Mayo Clinic. Importantly, researchers say the findings are not about choosing one treatment over another, but about better aligning treatment decisions with long-term healt

Inconsistent use of some GLP-1 weight-loss medications, like Ozempic and Wegovy, may significantly lessen their effectiveness, according to a preclinical study from researchers at the Perelman School of Medicine at the University of Pennsylvania. The study showed that each time overweight mice stopped and restarted GLP-1s, they dropped less and less weight compared their original weight-loss. “The effectiveness of these medications may depend heavily on consistency,” said Dr

Olympus Corporation has received FDA 510(k) clearance for the POWERSEAL Open Extended Jaw Sealer/Divider. This latest edition to the Olympus POWERSEAL advanced bipolar surgical energy portfolio supports clinical needs for precision, efficiency and control during surgery. POWERSEAL Open Extended Jaw Sealer/Divider The POWERSEAL Open Extended Jaw Sealer/Divider joins three 5mm devices in the POWERSEAL portfolio. These 5mm devices are offered in three jaw configurations, each av

People who live with obesity are "tagging" a memory of being overweight on a key part of the immune system - leaving people with ongoing risk of obesity-related conditions years after losing weight, according to a 10-year-long study led by University of Birmingham, UK. A European research team led by Professor Claudio Mauro from the University of Birmingham has shown that immune cells known as helper T cells (or CD4+ lymphocytes) carry a long memory of obesity. "The findings

Ascletis Pharma has completed enrolment in its 13-week US Phase II study evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of type 2 diabetes mellitus (T2D). T2D is the second indication for ASC30, following its first indication of obesity. Topline data from the Phase II study for the treatment of T2D are expected in the third quarter of 2026. The Phase II study is a 13-week, randomised, double-blind, placebo-controlled and multi-cent

A prospective randomised controlled pilot study by researchers from Mansoura University, Mansoura, Egypt, has demonstrated that concomitant laparoscopic cholecystectomy (LC) during bariatric surgery in patients with morbidly obesity with pre-existing gallstones is safe and feasible. Although concomitant LC results in longer operative time (mean increase of 23.75 min) and higher immediate postoperative pain scores, the researchers noted that these differences do not translate